Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Spero Therapeutics, Inc.

NASDAQ: SPRO · Life Sciences · 5 alerts · CIK 1701108

Share price
$0.9464Close, Nov 16
Market cap
$55.1M
Shares outstanding
58.26MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Spero Therapeutics, Inc. filings on SEC EDGAR ↗

4:44 PM ET 8-K
Financial Results

Spero Therapeutics Financial Results

Spero Therapeutics reported third quarter 2026 financial results, ending the period with $107.9 million in cash and cash equivalents. The company is focused on advancing its in-licensed anti-CD40L antibody, SP001, toward a Phase 2 trial in IgG4-related disease expected to initiate in Q2 2027.

“We believe SP001 represents a compelling opportunity to address significant unmet medical needs across multiple immune-mediated diseases. With a strong financial position and the recent additions to our team that strengthen the capabilities needed to support our next stage of development, we believe we are well positioned to execute our clinical development strategy.”

Esther Rajavelu, President and Chief Executive Officer
4:35 PM ET 10-Q
Financial Results

Spero Therapeutics Q3 2026 Results: Net Loss of $44.3M, Loss Widens

Spero Therapeutics reported that the FDA approved GSK’s NDA resubmission for Utebzi in June 2026, shifting the company's focus to the development of SP001. As of November 6, 2026, the company had 58,264,577 shares of common stock outstanding and continues to rely on milestone payments and royalties from its GSK partnership to fund operations.

Key figure
Net loss $44.3M
6:30 PM ET Form 4
Insider Selling

Spero Therapeutics Insider Esther Rajavelu Sells $42.5K of Stock

Esther Rajavelu sold 40,851 shares of Spero Therapeutics, Inc. at $1.04 a share, worth $42.5K in total on Nov 9, 2026. Shares held after the trade: 946,000 (-4.1%).

Value
$42.5K
Shares
40,851
Price
$1.04
Holding change
-4.1%
Trade date
Nov 9, 2026
5:31 PM ET 8-K
Leadership Change

Spero Therapeutics Leadership Change

Patrick Vink, M.D. resigned from the Board of Directors effective November 10, 2026, after 11 years of service. To fill the vacancy, the Board appointed William Ho, M.D., Ph.D., a former RAPT Therapeutics executive, as a Class II director and member of the Development Committee. Dr. Ho will receive an annual cash retainer of $45,000 and was granted an option to purchase 100,000 shares of common stock.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.